. We therefore studied the role of the sensory neuron cytoskeleton ments, microtubules, and intermediate filaments) markedly attenuated the hyperalgesia in rat paws in mechanical hyperalgesia induced in vivo in rat paws by two inflammatory mediators that act at G proteincaused by injection of epinephrine or its downstream mediators. In contrast, the hyperalgesia induced by coupled receptors and in sensitization of dorsal root ganglion (DRG) neurons in vitro. Using disruptors or PGE 2 or its mediators was not affected by any of the cytoskeletal disruptors. These effects were mimicked stabilizers of the three major structural components of the cytoskeleton-microfilaments, microtubules, and inin vitro, as measured by enhancement of the tetrodotoxin-resistant sodium current. When PGE 2 hyperalgetermediate filaments-we tested the dependence of receptor activation-induced second messenger signaling sia was shifted to dependence on PKC⑀ and ERK as well as PKA, as when the tissue is "primed" by prior on an intact cytoskeleton. We also tested whether changes that occur in second messenger mediation of treatment with carrageenan, it too became dependent on an intact cytoskeleton. Thus, inflammatory media- PGE 2 -induced hyperalgesia or baseline nociception at Prior exposure to carrageenan, an inflammatory stimany dose tested ( Figure 1C ). To confirm that the inhibiulus that produces hyperalgesia lasting approximately tion of EPI hyperalgesia by cytochalasins or latrunculins was due to actin disruption, we tested whether phalloidin could prevent cytochalasin D-induced loss of EPI
Introduction
Microfilaments To examine the role of microfilaments in hyperalgesia Inflammatory mediators, acting through G protein-couinduced by direct-acting inflammatory agents, we inpled receptors (GPCRs), sensitize the peripheral termijected intradermally in the dorsum of the hindpaws of nals of primary afferent nociceptors to cause a decrease rats the actin microfilament-disrupting agents cytochain pain threshold (Gold et al., 1998; Gold, 1999 (A) The effect of disrupting actin filaments with cytochalasin B (EPIϩCB; n ϭ 6), cytochalasin D (EPIϩCD; n ϭ 12), latrunculin A (EPIϩLatA; n ϭ 6), or latrunculin B (EPIϩLatB; n ϭ 6) on mechanical hyperalgesia induced by the direct-acting agent epinephrine (EPI; n ϭ 16).
(B) The effect of disrupting actin filaments with CB, CD, LatA, or LatB on mechanical hyperalgesia induced by the direct-acting agent prostaglandin E 2 (PGE 2 ; n ϭ 16). Values of n for PGE 2 ϩCB, PGE 2 ϩCD, PGE 2 ϩLatA, and PGE 2 ϩLatB are as with EPI ϩ the same agent in (A). Baseline paw withdrawal threshold (110.7 Ϯ 0.6, g Ϯ SEM) was not affected by actin disruptors, CB (n ϭ 12), CD (n ϭ 18), LatA (n ϭ 12), or LatB (n ϭ 12). (C) Dose-response relation of effects of LatA on hyperalgesia induced by EPI (n ϭ 6 for each dose) and PGE 2 (n ϭ 6 for each dose).
(D) Stabilization of actin cytoskeleton by a prior injection of rat paws with the actin filament stabilizer phalloidin blocked the attenuating effect of the microfilament disruptor cytochalasin D (PHAϩCDϩEPI; n ϭ 6) on epinephrine-induced hyperalgesia. The stabilizer was injected 1 hr preceding the disruptor. Injection of the disruptor was followed after 30 min by an injection of epinephrine (EPI; n ϭ 12). Phalloidin by itself had no effect on EPI-(EPIϩPHA; n ϭ 12) or PGE 2 -induced hyperalgesia (not shown) or on baseline paw withdrawal threshold (PHA; n ϭ 18). (E) Disrupting actin filaments also blocks the increase in the TTX-resistant sodium current caused by epinephrine in whole-cell patchclamp experiments. After establishing the whole-cell recording configuration, cells were perfused with either 5 M latrunculin A in normal bath (latrunculin, n ϭ 5) or bath alone (control, n ϭ 5) for 10-15 min. Epinephrine (1 M) was then perfused via the bath for 3 min starting at time 0. Currents were normalized to the mean amplitude of the 9 baseline responses before the application of epinephrine. The increase in TTX-R I Na caused by epinephrine was significantly attenuated by pretreatment with latrunculin A (p Ͻ 0.05, two-way repeated measures ANOVA). (F) Disrupting actin filaments had no effect on potentiation of TTX-R I Na by PGE 2 . Experiments were performed exactly as in (E) with 1 M PGE 2 replacing epinephrine (latrunculin, n ϭ 6; control, n ϭ 7). Scale of the y axis is expanded relative to (E), since the average increase in TTX-R I Na in response to PGE 2 is smaller than in response to epinephrine, due to the fact that only ‫%05ف‬ of cells expressing TTX-R I Na respond to PGE 2 while ‫%08ف‬ respond to epinephrine (Gold et al., 1996; Khasar et al., 1999b). In (A)-(D), all injections were made intradermally into the dorsum of the hindpaws. Each agent (disruptor or stabilizer) was injected 30 min preceding the administration of EPI or PGE 2 at the same site. Data is expressed as percentage change in the nociceptive threshold in grams (% Ϯ SEM). (*p Ͻ 0.0001; one-way ANOVA and Fisher's PLSD post hoc test; NS ϭ not significant).
hyperalgesia. Administration of phalloidin 1 hr preceding 1996). We tested whether the potentiation of TTX-R I Na by epinephrine or PGE 2 was differentially dependent on injection of cytochalasin D, followed after 30 min by an injection of EPI, significantly prevented the cytochaintact actin filaments, similar to epinephrine-and PGE 2 -induced hyperalgesia in vivo. Exposure of cultured DRG lasin-D-induced attenuation of EPI hyperalgesia (p Ͻ 0.0001; Figure 1D ). By itself, stabilization of actin filaneurons to 5 M latrunculin A in the perfusion bath for 10 to 15 min prior to the application of 1 M epinephrine ments by phalloidin did not significantly affect EPIinduced hyperalgesia (p Ͼ 0.05; Figure 1D ). None of the completely prevented the potentiation of TTX-R I Na (Figure 1E) . In contrast, the same treatment did not affect the agents that affect actin-either disrupting or stabilizing it-had an effect, by itself, on nociceptive threshold (all potentiation of TTX-R I Na by PGE 2 ( Figure 1F) , consistent with the lack of effect of latrunculin A on PGE 2 hyperalgep Ͼ 0.05; Figures 1A, 1B, and 1D ).
Epinephrine and PGE 2 produce hyperalgesia, at least sia. Latrunculin by itself had no effect on TTX-R I Na (data not shown). in part, by increasing peak inward current of the tetrodotoxin-resistant sodium current (TTX-R I Na ) and shifting its activation to more negative membrane potentials Microtubules To examine the role of microtubules in hyperalgesia through activation of their respective GPCRs and subsequent PKA signaling (Khasar et al., 1999a; Gold et al.,
induced by direct-acting agents, we injected rat hind- paws with the microtubule-disrupting drugs nocodasia by Colcemid (p Ͻ 0.0001; Figure 2D ). Taxol alone slightly but significantly enhanced hyperalgesia induced zole, Colcemid, or vincristine prior to injection of EPI and PGE 2 . All three disruptors significantly antagonized by EPI (p Ͻ 0.05; Figure 2D ) and by PGE 2 (data not shown). None of the agents that affect microtubules-EPI-induced hyperalgesia (all p Ͻ 0.0001; Figure 2A ) but had no effect on PGE 2 -induced hyperalgesia (all p Ͼ disrupting or stabilizing-had an effect on baseline nociceptive threshold (all p Ͼ 0.05; Figures 2A and 2B ). 0.05; Figure 2B ). We also injected Colcemid at several doses in order to confirm that the standard dose was
We also tested whether the in vitro potentiation of TTX-R I Na by epinephrine was dependent on intact microappropriate. Colcemid (1 ng to 1 g per 2.5 l) had a clear dose-response relationship in its effect against tubules. Exposure of cultured DRG neurons to 5 M Colcemid in the perfusion bath for 10 to 15 min prior to EPI-induced hyperalgesia, while at no dose did it have an effect on either baseline nociception or PGE 2 -induced the application of 1 M epinephrine completely prevented the potentiation of TTX-R I Na ( Figure 2E ). Colhyperalgesia ( Figure 2C ). To provide more evidence that the inhibition of EPI-induced hyperalgesia by nocodacemid by itself had no effect on TTX-R I Na (data not shown). zole, Colcemid, and vincristine was due to microtubule disruption, we tested whether Taxol could prevent the block of EPI hyperalgesia by Colcemid. We found that For up to a month after recovery from carrageenaninduced hyperalgesia, rats are sensitized to PGE 2 , which then produces a markedly prolonged hyperalgesic state acrylamide on hyperalgesia induced by EPI or PGE 2 .
Intermediate Filaments
in a phenomenon referred to as hyperalgesic priming While acrylamide significantly antagonized EPI-induced (Aley and Levine, 1999). PGE 2 -induced hyperalgesia durhyperalgesia (p Ͻ 0.0001), it had no effect on PGE 2 hying this primed state is mediated by both PKA (Aley and peralgesia (p Ͼ 0.05; Figure 3A Figure 5B ). PGE 2 -induced hyperalgesia was not inhibited by ERK inhibitors in control rats, i.e., in rats and electrophysiology studies, we used immunocytochemistry and confocal microscopy to visualize the cythat had not been previously treated with carrageenan (p Ͼ 0.05; Figure 5C ). We then tested the hypothesis toskeleton of cultured DRG neurons (1 day in vitro) that were treated with a representative disrupting agent for that the prolonged hyperalgesia induced by PGE 2 in hindpaws previously treated with carrageenan is depeneach of the three components of the cytoskeleton. Cells were treated with 10 M cytochalasin D (or DMSO vehident on the cytoskeleton. After a 96 hr recovery from carrageenan-induced hyperalgesia ( Figures 5A and 5D , cle as control) for 15 min or 1 hr, fixed, and stained with Figure 5D, right) . When the actin disruptor Lat A was injected 30 min before PGE 2 We then asked whether the hyperalgesic effects of activating the PKA, PKC⑀, or ERK second messenger sysin the same paradigm, hyperalgesia seen at 0.5, 4, and 24 hr after PGE 2 was significantly inhibited (p Ͻ 0.0001; tems, independent of receptor activation, were also dependent on the cytoskeleton. The hyperalgesia caused Figure 5D , right). Figures 6A and 6B) . In contrast, ceptors are very thin and their relative density in perithe hyperalgesia induced by injection of the PKC⑀ actipheral tissue low, it is not possible to directly assess vator, ⑀-RACK, and the ERK activator, active MEK, was cytoskeletal function in these terminals. However, noncompletely inhibited by each of these three cytoskeletal specific effects of cytoskeleton disruptors are unlikely to disruptors (Figures 6C and 6D) . Therefore, hyperalgesia account for our findings for several reasons: (1) multiple caused by independent activation of PKC⑀ or ERK is disruptors of each element produced the same effect, (2) dependent on an intact cytoskeleton, while that caused in normal rats disruptors have no effect on hyperalgesia by independent activation of PKA is not.
induced by the direct-acting agent PGE 2 , while (3) they do block PGE 2 -induced hyperalgesia in carrageenanDiscussion primed rats, (4) sensitization of TTX-R I Na by EPI but not PGE 2 in cultured DRG neurons is also affected by We examined the role of cytoskeletal elements in orcytoskeletal disruption, and (5) the time course for disganizing transduction mechanisms for the production of ruption of hyperalgesia in vivo is similar to the time hyperalgesia by inflammatory mediators that act directly course for disruption of the cytoskeletal elements seen on the peripheral terminals of primary afferent nocicepin vitro. Since it has previously been shown in other tors through G protein-coupled receptors (GPCRs). In model systems that stabilizers of cytoskeleton can pronormal male rats, intact actin filaments, microtubules, tect against the effect of disruptors (Karbowski et al., and intermediate filaments are all necessary for EPI-2001), we also determined that cytoskeleton stabilizers induced hyperalgesia, while PGE 2 -induced hyperalgesia could block attenuation of EPI hyperalgesia produced appears to be independent of the state of the cytoskeleby disruptors; another indication of the specificity of ton. In addition, we demonstrate plasticity in this cyaction of the disruptors. Effects of the cytoskeletal distoskeletal dependence. Thus, following exposure to ruptors acting on other cells present in dermal tissue is also unlikely, due to the fact that EPI clearly acts directly carrageenan, PGE 2 -induced hyperalgesia becomes de- , and 24 hr after PGE 2 , which was injected after a 4-5 day were permeabilized with 0.1% Triton X-100 in PBS buffer type 1 for 5 min at room temperature. Cells were stained for 45 min at room recovery from carrageenan treatment. It has been shown in previous studies that agents injected using the protocol described exert a temperature with FITC-phalloidin (0.5 mg/ml, Sigma) diluted in PBS buffer type 1 ϩ 0.1% Triton X-100. Nonspecific PHA-FITC binding peripheral rather than central action (Khasar et al., 19995, 1999a ). All behavioral testing was done between 10 am and 4 pm. Because was performed by pretreating fixed, permeabilized cells with unlabeled phalloidin prior to addition of FITC-labeled phalloidin. Cells they are less membrane permeable, injections of protein kinase A catalytic subunit (PKA-CS), protein kinase ⑀ agonist (⑀-RACK), and were washed in supplemented PBS buffer type 1 and incubated for 10 min at room temperature with propidium iodide (1 mg/ml; Sigma) active MEK were always preceded by administration of 2.5 l of distilled water in the same syringe to produce hypo-osmotic shock, for nuclear localization. For tubulin and neurofilament staining, the thereby enhancing cell membrane permeability (Khasar et al., 1995;  cells test pulse was applied from a holding potential of Ϫ60 mV every 20 1987) before they were used for confocal microscopy and in vitro s to monitor the amplitude of TTX-R I Na during the experiment. A patch-clamp electrophysiology. Cells were used during the first 24 voltage that produced approximately half-maximal current activahr after plating. tion was used for the test pulse because hyperalgesic agents produce the greatest increase in TTX-R I Na at this part of the I-V curve (Gold et al., 1996). Latrunculin A and Colcemid or control solution In Vitro Drug Treatment and Fluorescence Microscopy were applied via bath perfusion for 10 to 15 min before application Cultured DRG neurons were incubated with cytoskeletal disruptors of 1 M EPI. Currents were averaged into 1 min bins and normalized at concentrations and for incubation times chosen to mimic in vivo for each cell to the mean amplitude of the nine responses immediadministration. Cytochalasin D, diluted in DMSO, was used at a final ately before epinephrine application. concentration of 10 M; nocodazole, diluted in DMSO, was used at 5 M; and acrylamide, diluted in phosphate-buffered saline (PBS), was used at 4 mM. Final concentration of DMSO, added to the cells, Data Analysis was 0.05%-0.2%, which alone had no effect on cell behavior or Group data are presented as mean Ϯ SEM and comparisons beorganization of the actin cytoskeleton (Cramer et al., 2002) . tween groups were done using Student's t test or analysis of variFor actin staining, the cells were plated on coverslips, washed in ance (ANOVA) followed by Fisher's protected Least Significant Dif-PBS, and fixed in 2% paraformaldehyde (PFA) in PBS for 10 min at ference (PLSD) post hoc test, as appropriate. A probability of p Ͻ room temperature. After three washes in supplemented PBS buffer type 1 (PBS ϩ 1% BSA ϩ 1 mM CaCl 2 ϩ 1 mM MgCl 2 ), the cells 0.05 was considered significant.
